1-TRC105 is a Phase 2 monoclonal antibody that binds CD105 (endoglin), a membrane receptor on endothelial cells that is required for angiogenesis; it is expected to complement chemotherapy and treatment with VEGF inhibitors, including Avastin(R) or Lucentis(R). 2-TRC102 is a Phase 2 ready small molecule inhibitor of base excision repair that reverses resistance to antimetabolite and alkylating agent chemotherapies
Start Trial Get Full Profile
There’s no risk. Start your trial today to see profiles of TRACON Pharmaceuticals (aka TRACON PHARMA) plus 4860 other startups.